Shinbaiyo Pharmaceutical (4582) announced that it has acquired the Japanese patent for IV BCV in malignant lymphoma—accelerating its expansion into the cancer field

SymBio Pharmaceuticals (4582)140 yen+33

March16 day, announced the acquisition of the Japan use patent for “IV BCVIV for malignant lymphoma―to accelerate expansion into oncology―.”IV BCV (the injectable blinusidovirl) malignant lymphoma use patent, we have received notification of patent registration from the Japan Patent Office. This patent is based on results obtained through our collaborative research with the National Cancer Center Singapore.